Article Figures & Data
Figures
- FIGURE 1.
18F-FET PET, contrast-enhanced MRI, and FLAIR MRI of 89-y-old patient with recurrent IDH–wild-type glioblastoma. Metabolically active tumor as identified by increased uptake of 18F-FET (threshold of 1.6 based on mean tumor-to-brain ratio) is outlined and projected onto MR images (red contour). Extent of metabolically active tumor on 18F-FET PET exceeds contrast-enhancing tumor portion and shows considerable spatial discrepancies from area of FLAIR hyperintensities. CE = contrast-enhanced.
- FIGURE 2.
A 68-y-old woman with brain metastasis secondary to renal cell carcinoma who underwent anatomic MRI and 18F-FDOPA PET. Twelve months after resection with postoperative radiosurgery, MRI suggested local tumor recurrence. In contrast, 18F-FDOPA PET showed no increased metabolic activity (mean tumor-to-brain ratio, 1.0) indicating treatment-related changes such as radiation injury. Diagnosis was confirmed by subsequent neuroimaging 3 mo later, including amino acid PET and anatomic MRI, demonstrating unchanged imaging findings and stable clinical course without any therapeutic intervention. CE = contrast-enhanced.
- FIGURE 3.
A 45-y-old woman with IDH–wild-type glioblastoma who underwent partial resection and radiotherapy with temozolomide plus lomustine chemotherapy as first-line treatment. Twenty-two months later, contrast-enhanced MRI and 18F-FET PET were consistent with tumor progression (left). For treatment, temozolomide chemotherapy was initiated. After 3 cycles, clear decrease in maximum tumor-to-brain ratios (−28%) was observed, whereas MRI showed only slight decrease in contrast enhancement (right). Metabolic response was associated with progression-free survival of 6 mo after temozolomide initiation. CE = contrast-enhanced; TBRmax = maximum tumor-to-brain ratio.
